{
    "Clinical Trial ID": "NCT00089479",
    "Intervention": [
        "INTERVENTION 1: ",
        "  AC Then T",
        "  Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2; repeat every 3 weeks for 4 cycles",
        "INTERVENTION 2: ",
        "  AC Then XT",
        "  Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Xeloda 825 mg/m^2 po (bid) [total daily dose is 1650 mg/m^2] Days 1-14 every 3 weeks for 4 cycles plus Taxotere 75 mg/m^2 iv every 3 weeks for 4 cycles"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  female patients 18-70 years of age;",
        "  adenocarcinoma of the breast;",
        "  previous invasive breast cancer if diagnosed >5 years before entering study;",
        "  no evidence of metastatic disease.",
        "Exclusion Criteria:",
        "  history of severe hypersensitivity reaction to Taxotere;",
        "  previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane;",
        "  treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Disease Free Survival [Number of Events]",
        "  Number of patients with/without recurrence of breast cancer, or death due to any cause.",
        "  Time frame: Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.",
        "Results 1: ",
        "  Arm/Group Title: AC Then T",
        "  Arm/Group Description: Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2; repeat every 3 weeks for 4 cycles",
        "  Overall Number of Participants Analyzed: 1304",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Patients with event: 164",
        "  Patients without events: 1140",
        "Results 2: ",
        "  Arm/Group Title: AC Then XT",
        "  Arm/Group Description: Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Xeloda 825 mg/m^2 po (bid) [total daily dose is 1650 mg/m^2] Days 1-14 every 3 weeks for 4 cycles plus Taxotere 75 mg/m^2 iv every 3 weeks for 4 cycles",
        "  Overall Number of Participants Analyzed: 1307",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Patients with event: 140",
        "  Patients without events: 1167"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 264/1305 (20.23%)",
        "  FEBRILE NEUTROPENIA 118/1305 (9.04%)",
        "  NEUTROPENIA 10/1305 (0.77%)",
        "  ANAEMIA 0/1305 (0.00%)",
        "  LEUKOCYTOSIS 2/1305 (0.15%)",
        "  LEUKOPENIA 1/1305 (0.08%)",
        "  PANCYTOPENIA 0/1305 (0.00%)",
        "  MYOCARDIAL INFARCTION 1/1305 (0.08%)",
        "  SUPRAVENTRICULAR TACHYCARDIA 2/1305 (0.15%)",
        "  ANGINA UNSTABLE 0/1305 (0.00%)",
        "  ATRIAL FLUTTER 0/1305 (0.00%)",
        "Adverse Events 2:",
        "  Total: 200/1283 (15.59%)",
        "  FEBRILE NEUTROPENIA 80/1283 (6.24%)",
        "  NEUTROPENIA 11/1283 (0.86%)",
        "  ANAEMIA 5/1283 (0.39%)",
        "  LEUKOCYTOSIS 0/1283 (0.00%)",
        "  LEUKOPENIA 0/1283 (0.00%)",
        "  PANCYTOPENIA 1/1283 (0.08%)",
        "  MYOCARDIAL INFARCTION 1/1283 (0.08%)",
        "  SUPRAVENTRICULAR TACHYCARDIA 0/1283 (0.00%)",
        "  ANGINA UNSTABLE 1/1283 (0.08%)",
        "  ATRIAL FLUTTER 1/1283 (0.08%)"
    ]
}